● neutral
Impact
PhaseCommercially Available (LDT)
Time to marketAlready commercially available in the U.S. as a laboratory developed test (LDT) through the company's CLIA-certified lab. CMS reimbursement has been in effect since January 2024.
CyPath Lung Updated Nov 17
What to watch
CyPath Lung is already commercial and generating revenue, so the next catalysts are commercial execution metrics (quarterly sales growth, test volumes, physician adoption) and data readouts from the large-scale longitudinal clinical study initiated in March 2026. The stock has fallen ~90% from its 52-week high and recently dipped after Q3 earnings, making sustained sales acceleration the key swing factor for the shares.
Bull case
- CyPath Lung is a noninvasive, sputum-based test with strong published performance (92% sensitivity, 87% specificity, 88% accuracy) for early-stage lung cancer detection.
- Commercial momentum is accelerating: sales more than doubled through Q3 2026 year-over-year, with a record 235 tests performed in October 2026.
- CMS has a final payment determination in place (effective January 2024), providing a clear Medicare reimbursement pathway.
Bear case
- Revenue remains tiny ($1.07M in Q3 2026) and the company is unprofitable, requiring repeated capital raises (a $4M direct offering closed in October 2026).
- The stock has lost roughly 90% from its 52-week high of $80.70, trading near $1.90, signaling severe market skepticism.
- Analyst consensus is weak: 0 buy, 3 hold, 1 sell, 2 strong sell (March 2026 snapshot).